Superiority of Alternating Non-Cross-Resistant Chemotherapy in Extensive Small Cell Lung Cancer

A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

1979 • 1,331 citations

Rationale for the use of alternating non-cross-resistant chemotherapy.

1982 • 545 citations

VP-16 and cisplatin as first-line therapy for small-cell lung cancer.

1985 • 301 citations

Small cell lung cancer 1973–1983: Early progress and recent obstacles

1984 • 219 citations

A randomized combined modality trial in small cell carcinoma of the lung comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation

1980 • 210 citations

Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.

1985 • 188 citations

Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma.

1979 • 179 citations

cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung.

1979 • 153 citations

Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.

1987 • 146 citations

Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung.

1984 • 114 citations

Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy.

1981 • 114 citations

Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung

1986 • 72 citations

Combined Modality Treatment of Small Cell Carcinoma of the Lung

1981 • 61 citations

Small-cell carcinoma of the lung: the prognostic significance of stage on survival

1979 • 16 citations